(2019) International multicenter randomized, placebo-controlled phase III clinical trial of β-D-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology. ISSN 1568-5608

(2018) Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. pp. 495-500. ISSN 1950-6007

(2018) Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial. International immunopharmacology. pp. 112-117. ISSN 1878-1705

(2017) Introduction of β-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene expression. Pharmacological Reports.